LEO Pharma has initiated a phase 2a trial investigating delgocitinib cream in adults with mild-to-severe palmoplantar pustulosis (PPP). The DELTA NEXT study will analyse the efficacy and safety of the therapy compared with cream vehicle across sites in the US, UK, Germany, Poland and Canada. PPP is a chronic, relapsing inflammatory skin condition characterised by […]
The post LEO Pharma initiates phase 2a trial of delgocitinib cream for rare skin condition appeared first on Pharmafile.
